Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A clinical-stage life science company developing the proprietary formulation Gemini to rebalance inflammation. Key product candidates include GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), GEM-PSI (post-surgical infection), and GEM-PBI (severe burn infection).
Capital Structure Events: The Company effected a 1-for-16 reverse stock split in January 2025 and a 1-for-3 reverse stock split in July 2025. All share data reflects these splits.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1.91) million | $(2.24) million | $(6.40) million | $(13.31) million |
| Net Loss Attributable to Common Stockholders | $(4.68) million | $(2.24) million | $(12.35) million | $(13.31) million |
| Operating Expenses | $1.94 million | $1.80 million | $6.50 million | $6.22 million |
| Cash and Cash Equivalents (End of Period) | $12.71 million | $6.54 million | $12.71 million | $6.54 million |
| Accumulated Deficit | $(46.91) million | $(38.78) million | $(46.91) million | $(38.78) million |
| Stockholders' Equity | $11.00 million | $2.67 million | $11.00 million | $2.67 million |
Note: Net loss attributable to common stockholders includes significant "deemed dividends" of $2.77 million for Q3 2025 and $5.95 million for 9M 2025 resulting from warrant exercise price reductions.
Material Changes vs. Prior Period
- Financing Activity: The Company raised significant capital in 2025. Proceeds included $3.4 million from a May 2025 Public Offering and $8.7 million from a September 2025 Class H Warrant Inducement. This contrasts with 2024, which saw $5.4 million from a February offering and $3.5 million from warrant inducements.
- Cash Position: Cash and cash equivalents increased from $6.5 million at September 30, 2024, to $12.7 million at September 30, 2025, driven by financing inflows of $12.5 million in the first nine months of 2025.
- Operating Expenses: Total operating expenses increased slightly by $0.28 million (4.5%) for the nine months ended September 30, 2025, compared to the prior year period. R&D expenses rose primarily due to increased clinical study costs.
- Other Income/Expense: The Company reported a significant improvement in "Other income (expense), net," turning from a $7.1 million expense in 9M 2024 (driven by legal settlements and underwriting commissions) to a $0.1 million income in 9M 2025 (driven by interest income).
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has raised substantial doubt about the Company's ability to continue as a going concern. The Company expects current cash resources ($12.7 million) to be insufficient to sustain operations for one year following the issuance of these financial statements. Additional equity or debt financing is required to continue operations.
Unusual Items
- Deemed Dividends: Significant non-cash charges were recorded due to "down-round" provisions in warrant agreements triggered by new financings and reverse stock splits. These reduced the exercise prices of existing warrants, resulting in deemed dividends of approximately $6.0 million for the nine months ended September 30, 2025.
- Warrant Inducements: The Company actively utilized warrant inducements to raise capital, issuing new warrants (Class I) in exchange for the cash exercise of existing warrants (Class H).
Risks
- Regulatory Uncertainty: Recent reductions in FDA staffing and changes in federal policy may delay clinical trial reviews and marketing approvals.
- Capital Availability: Failure to secure additional funding could force the Company to delay, reduce, or eliminate R&D programs.
- AI and Technology: Potential reliance on AI for drug discovery carries risks regarding data quality, regulatory compliance, and third-party vendor failures.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of any ongoing fundraising efforts to address the "Going Concern" warning.
- Dilution Impact: Review the terms of the Class I Warrants and other outstanding warrant classes (Class C, D, G, H) to understand the potential dilution from the large number of shares reserved for issuance (~20.7 million shares).
- Clinical Progress: Confirm the status and budget requirements for the GEM-AKI, GEM-CKD, GEM-PSI, and GEM-PBI clinical trials, as these drive future cash burn.
- Warrant Liability: Monitor the fair value of the warrant liability (currently $175) and the impact of future stock price movements on the balance sheet.